Inclusion Criteria:  Non-smoking, healthy male or female subjects aged 18-59 years. Body Mass Index (BMI) of ≥ 19.0 and ≤ 30.0 kg/m2. 12-Lead electrocardiogram (ECG) evaluation without clinically significant abnormalities. Normal renal function, including having a creatinine clearance (CLcr) ≥90mL/min Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception. Screening laboratory assessments must be without clinically significant abnormalities as assessed by the investigator.  Exclusion Criteria:  Pregnant and lactating females Have received any investigational drug (or vaccine) within the last 30 days prior to study dosing. Have a positive test result for HIV or HBsAg. Have poor venous access that limits phlebotomy Have taken any prescription medications or over-the-counter medications, including herbal products and dietary supplements within 28 days prior to start of study. Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to Screening or is expected to receive these agents during the study. Have a history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. Have a history of significant drug sensitivity, cardiac disease, syncope, palpitations, or unexplained dizziness, implanted defibrillator or pacemaker, liver disease, severe peptic ulcer disease, gastroesophageal reflux disease and a medical or surgical treatment that permanently altered gastric absorption. Have received inactivated vaccinations within 4 weeks prior to randomization or receive live vaccinations within 4 weeks of Screening. Received the COVID-19 vaccine either within 7 days or have not completed the series of required 2 doses. Have a history of excessive alcohol use or other illicit drug use within 6 months of screening.